



# NATIONAL PATIENT ADVOCATE FOUNDATION

*A National Network for Healthcare Reform*

Nancy Davenport-Ennis  
Chief Executive Officer

#### EXECUTIVE BOARD

William T. McGivney, PhD  
Immediate Past Board President  
Chief Executive Officer  
National Comprehensive Cancer Network  
Edward G. Connette, Esquire  
Board President  
Essex Richards, PA

Christian Downs, MHA, JD  
Board Vice President  
Executive Director  
Association of Community Cancer Centers  
Leah Arnett, RN, BSN, MHCA  
Board Secretary  
Nursing Director, University Health Services  
University of Texas at Austin

John L. Murphy  
Board Financial Officer  
Saguemay Capital, LLC

Don Conway, MD  
Board Financial Officer  
Director, The Healthcare Initiative  
Tuck School of Business  
Dartmouth College

Bruce Avery, MD  
Hematology-Oncology Knoxville

Roy A. Beveridge, MD  
Co-Director, Stem Cell Transplant Center  
Inova Fairfax Hospital

Dennis A. Gastineau, MD  
Director, Human Cell Therapy Laboratory  
Divisions of Transfusion Medicine  
and Hematology  
Mayo Clinic

Richard D. Carter, Esquire  
Carter & Lay

The Honorable Phil Hamilton  
Virginia House of Delegates  
Sheldon Weinhaus, Esquire  
Weinhaus & Potashnick

Rene S. Cabral-Daniels, JD, MPH  
Director  
Office of Health Policy and Planning  
Virginia Department of Health

#### SCIENTIFIC BOARD

Lori Williams, DSN, RN, AOCN  
Chair, Scientific Board of Directors  
University of Texas

MD Anderson Cancer Center  
Houston School of Nursing  
Otis W. Brawley, MD  
Professor, Emory School of Medicine  
Emory University

David Brizel, MD  
Professor

Duke University Medical System  
Radiation Oncology Department  
Robert M. Rifkin, MD, FACP  
Director, Cellular Therapeutics  
Rocky Mountain Blood  
& Marrow Transplant Program  
Rocky Mountain Cancer Centers

F. Marc Stewart, MD  
Medical Director, SCGA  
Professor of Medicine  
University of Washington  
Fred Hutchinson Cancer Research Center  
Richard L. Theriault, DO, MBA  
Professor of Medicine  
MD Anderson Cancer Center

#### HONORARY BOARD

The Honorable Mary T. Christian  
John H. Ennis, Jr., Co-Founder  
Chief Development Officer

Pearl Moore, RN, MN, FAAN  
Director, Essex House

Paula Trahan-Rieger, RN, MSN, AOCN, FAAN  
Chief Executive Officer  
Oncology Nursing Society

Leo E. Sands  
Executive Vice President &  
Chief Administrative Officer  
U.S. Oncology

Doris Simonson

April 2007

## RE: SB 674—Coverage for routine care costs associated with clinical trials

The National Patient Advocate Foundation (NPAF) is keenly interested in legislation such as Senate Bill 674, which requires insurers to cover routine care costs associated with clinical trials.

To ensure that the coverage applies equally to all situations in which individuals may be participants in clinical trials, we urge the legislation to include among entities that can approve a clinical trial “an Institutional Review Board (IRB) which oversees industry and community trials.” In addition, we urge that legislation regarding coverage for routine care costs include the following criteria:

- Requires coverage for all four phases of clinical trials for cancer
- Requires coverage for adults and children
- Requires coverage for out-of-state clinical trials

Participation in clinical trials is essential for the continued development of new medications to effectively treat and/or cure patients with chronic and life-threatening illnesses; unfortunately, only 5% of cancer patients participate in clinical trials. A significant barrier to clinical trial participation is lack of insurance coverage for routine care costs such as office visits, hospital stays, laboratory tests, or other services that would normally be covered if the patient were not enrolled in a clinical trial. This added financial burden can discourage patient participation and slow the development of new, innovative treatments.

Several states have passed legislation requiring insurance companies to cover routine care costs during clinical trials. As of the submission of this letter, the following states have taken action on this issue: Arizona, California, Connecticut, Delaware, Georgia, Louisiana, Maine, Maryland, Massachusetts, Michigan, Missouri, Nevada, New Hampshire, New Jersey, New Mexico, North Carolina, Ohio, Rhode Island, Tennessee, Vermont, Virginia, West Virginia and Wisconsin. For specific information about the legislative action taken in those states, visit the National Cancer Institute website at <http://www.cancer.gov/clinicaltrials/developments/laws-about-clinical-trial-costs>

National Patient Advocate Foundation (NPAF) is dedicated to improving access to care through legislative and policy reform at both the state and federal levels. NPAF advocacy activities are influenced by the experience of the patients we serve through our companion organization, Patient Advocate Foundation (PAF). PAF provides case management services directly to patients at no charge to help resolve insurance, job retention, and/or debt crisis matters relative to a serious diagnosis. In 2006, over 6 million Americans contacted Patient Advocate Foundation with a request for assistance. We invite you to review the NPAF and PAF websites to learn more about both organizations: [www.npaf.org](http://www.npaf.org) and [www.patientadvocate.org](http://www.patientadvocate.org)

On behalf of NPAF’s Texas volunteer State Policy Liaison, Colby Jackson, the NPAF Advocates Network volunteers in Texas, and NPAF’s State Government Affairs, thank you for your work to expand coverage for routine care costs associated with clinical trials. If we can be of assistance in this work, please don’t hesitate to contact your Texas NPAF State Policy Liaison or NPAF State Government Affairs at 866-706-4977.